| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 119.59 | 22.0% | 19.3% |
| Total Income | 119.59 | 22.0% | 19.3% |
| Expenditure | 68.74 | 14.9% | 33.4% |
| PBT | -108.02 | 146.1% | 248.8% |
| Net Profit | -83.42 | 144.7% | 231.0% |
| OPM | 42.52% | 3.59pp | 6.09pp |
| NPM | -69.75% | 169.75pp | 133.26pp |
| EPS | -1.14 | 145.2% | 212.9% |
Innoviva Reports Q2 2026 Financial Results with 19% Revenue Growth
06 Aug 2026 · 6 Aug, 1:54 am
Summary
Innoviva, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting a 19% increase in total revenue to $119.6 million, driven by strong performance in net product sales which grew 46% year-over-year. The company highlighted robust commercial momentum at its Innoviva Specialty Therapeutics (IST) division, with U.S. net product sales up 26%. Despite a net loss of $83.4 million due to investment fair value changes, management expressed confidence in the company's diversified business model and strategic growth opportunities, including the launch of Nortiva Bio.
Key Highlights
- 1
Innoviva reported total revenue of $119.6 million for the second quarter of 2026, representing a 19% year-on-year growth.
- 2
Net product sales grew by 46% to $51.8 million in the second quarter of 2026 compared to $35.5 million in the second quarter of 2025.
- 3
U.S. net product sales reached $36.6 million in the second quarter, marking a 26% year-over-year increase.
- 4
Royalty revenue remained stable at $59.8 million in the second quarter of 2026.
- 5
Income from operations was $50.9 million for the second quarter of 2026, an increase from $48.8 million in the prior year period.
- 6
The company reported a net loss of $83.4 million, or $1.14 basic loss per share, for the second quarter of 2026, primarily driven by unfavorable changes in the fair value of investments.
- 7
Innoviva launched Nortiva Bio, a new platform focused on novel extended-release drug delivery technology.
Management Comments
Pavel Raifeld
Innoviva delivered another strong quarter, supported by durable cash generation from our royalty portfolio and continued excellent commercial momentum at IST, which achieved 46% year-over-year net product sales growth, including 26% growth in U.S. sales. We remain on track to achieve at least $150 million in IST U.S. net product sales in 2026, reflecting the differentiation of our marketed critical care and infectious disease portfolio and robust execution. Recently, we also advanced several growth opportunities. This quarter, we announced a commercialization and licensing agreement with Dr. Reddy’s Laboratories, expanding access to our top-performing antibiotic, XACDURO, in emerging markets. Additionally, we launched Nortiva Bio, a novel platform for long-acting oral medicine delivery, with large upside potential. Overall, we have been pleased with progress across our healthcare asset portfolio, despite market volatility. Our continued activity under the share repurchase program reflects our sustained conviction in the long-term prospects of our diversified business model — one that combines durable cash generation, strong operating revenue growth, and value creation in high-potential strategic opportunities.
Informational and educational content only. Not investment advice.